BridgeBio Pharma (BBIO) Current Assets (2018 - 2026)

BridgeBio Pharma has reported Current Assets for 9 years, with the latest figure at $1.2 billion in Q1 2026.

• Quarterly Current Assets rose 78.56% year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 78.56% YoY) and the FY2025 annual result came in at $797.7 million, up 10.69% from the prior year.
• Current Assets grew to $1.2 billion in Q1 2026 per BBIO's latest filing, from $797.7 million in the prior quarter.
• Over five years, Current Assets peaked at $1.2 billion in Q1 2026 and troughed at $432.9 million in Q2 2023.
• A 5-year average of $693.0 million and a median of $695.2 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets slumped 43.87% in 2023, then jumped 88.8% in 2025.
• Over 5 years, Current Assets stood at $548.9 million in 2022, then decreased by 12.98% to $477.6 million in 2023, then surged by 50.9% to $720.7 million in 2024, then gained by 10.69% to $797.7 million in 2025, then surged by 55.6% to $1.2 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.2 billion, $797.7 million, and $839.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.